Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TPC-1 and SW1736 human thyroid carcinoma cells were used.
|
31102069 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide LAR has modest in vivo efficacy and the combination of everolimus and pasireotide LAR achieve greater tumor growth inhibition than each agent alone in TPC-1 xenograft model of thyroid cancer (p = 0.048).
|
30807575 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic (8505C, CAL62, SW1736) and papillary (TPC-1) thyroid cancer cell lines were used to dissect the role of miR-650 on malignant hallmarks of transformation.
|
30927143 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further confirm its role on autophagy, we knockdown FAM129A in two thyroid carcinoma cell lines (TPC1 and FTC-236).
|
30400008 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TPC-1 and SW1736 thyroid carcinoma cells were used.
|
30396956 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.
|
30127885 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SW1736 and TPC-1 human thyroid carcinoma cells were used.
|
29285650 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our purpose was to study the combined effect of HDAC inhibitors (HDACi) and ionizing irradiation in thyroid cancer cell lines (Nthy-ori 3-1, WRO, TPC-1 and 8505c).
|
30125607 |
2018 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of YAP1 significantly increased in the thyroid carcinoma cell line compared with normal thyroid cells, among which the expression of YAP1 in TPC-1 was the highest.
|
29762852 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the biological role of LRP4 in the thyroid cancer in the present study was investigated using the PTC cell lines TPC1, BCPAP and KTC-1.
|
29885843 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the activities of hydroxytyrosol against papillary (TPC-1, FB-2) and follicular (WRO) thyroid cancer cell lines.
|
27592355 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To show effects of runx2 transcription factor on gal-3 expression, we developed runx2 knockdown model in the thyroid carcinoma cell lines; anaplastic 8505C and 8305C and, papillary TPC-1 and follicular FTC-133 by using siRNA transfection.
|
28390192 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, a knockdown of galectin-1 in papillary (TPC-1) and anaplastic (8505C) thyroid cancer cell lines was achieved by lentiviral transduction for in vitro experiments.
|
28677745 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SW1736 and TPC-1 human thyroid carcinoma cells were used.
|
28982310 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of HOTAIR significantly inhibited cell growth and invasion in TPC-1 and SW579 human thyroid carcinoma.
|
28565838 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this purpose, cell lines derived from papillary (TPC-1 and BHP 10-3) and anaplastic (ARO) thyroid carcinomas were stably transfected with expression vectors containing TTF-1 or PAX-8 genes.
|
27573549 |
2016 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To demonstrate that miR-106b reduces C1orf24 expression, follicular (WRO) and papillary (TPC1) thyroid carcinoma cell lines were transiently transfected with miR-106b mimic.
|
26317551 |
2015 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that a TRAIL-R2 agonist antibody, lexatumumab, induces apoptosis effectively in some thyroid cancer cell lines (HTh-7, TPC-1 and BCPAP), while more aggressive anaplastic cell lines (8505c and SW1736) show resistance.
|
24603332 |
2014 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using 76 papillary thyroid cancer(PTC) tissues and three thyroid cancer cell lines (TPC1, WRO82-1 and XTC), the expression of three genes and DNA methylation were determined by reverse transcription-PCR and methylation-specific PCR.
|
24222120 |
2013 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 3 thyroid cancer cell lines (TPC1 from a papillary thyroid cancer, FTC133 from a follicular thyroid cancer, XTC1 from a Hürthle cell carcinoma), small interfering RNA knockdown of RTN4IP1 was used to determine its role in regulating the hallmarks of malignant cell phenotype (cellular proliferation, migration, apoptosis, invasion, tumor spheroid formation, anchorage independent growth).
|
23393170 |
2013 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three anaplastic (Hth74, C643, Kat4), one follicular (FTC133), and one papillary (TPC1) TC cell lines were used.
|
22006286 |
2012 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E).
|
21355020 |
2011 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E (8505C, BCPAP, SW1736, BHT101), NRAS Q61R (HTH7), KRAS G12R (CAL62), HRAS G13R (C643), or RET/PTC1 (TPC-1) oncogenes.
|
19880792 |
2010 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib.
|
19878585 |
2009 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We, therefore, investigated the expression of VEGF messenger RNA (mRNA) and production of VEGF protein in cell lines from human primary and metastatic follicular (FTC-133, FTC-236, and FTC-238), papillary (TPC-1), Hürthle cell (XTC-1), and medullary thyroid cancers (MTC-1.1 and MTC-2.2), and in human thyroid tissues (papillary, follicular, medullary, and Hürthle cell cancers, follicular adenomas, and Graves' thyroid tissue) by Northern blot, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA) studies.
|
9360534 |
1997 |